[Ki-67 proliferative index in patients with early breast cancer]
Gonzalez L, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L
Record ID 32015001150
Spanish
Authors' recommendations:
The evidence supporting Ki-67 proliferative index as prognostic factor in women with early breast cancer is of moderate methodological quality. This is based on the retrospective analysis of selected and heterogeneous samples of patients, which suggest that a high index would be associated with higher chances of recurrence and death due to breast cancer.
The results on its ability to predict the benefit of adjuvant chemotherapy in those patients with high index come from low methodological quality studies which also show contradictory results.
There is no consensus among the main international societies on its systematic use in patients with early breast cancer. Not having a defined cut-off value to determine an index as high or studies assessing changes in treatment decision making and its subsequent clinical impact, limit its recommendation.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.iecs.org.ar/publicacion/?id=5287
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Humans
- Breast Neoplasms
- Ki-67 Antigen
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.